The Ly Laboratory studies how cell cycle defects and mitotic errors shape the complex mutational landscape of human cancer genomes.

Our mission is to understand the most fundamental questions in cancer biology, such as tumor initiation, progession, and response to therapy, through state-of-the-art experimentation, fruitful collaborations and, above all, out-of-the box thinking to develop novel, safe(r) and more effective therapies to win the fight against cancer!

The Jewell Lab investigates how organisms sense environmental nutrient fluctuations and respond appropriately, fine tuning anabolic and catabolic processes to control cell growth, metabolism, and autophagy.

 In diseases like cancer, signaling pathways can be corrupted by mutations that cause the cells to grow and spread uncontrollably. Our lab is interested in understanding how these defective pathways reprogram cellular metabolism to drive cancer growth.

We are multidisciplinary team of clinicians and scientists, focusing on liver cancer risk-predictive molecular biomarkers specific to clinical contexts (ex. geographic region, liver disease etiology, and patient race/ethnicity) individual risk-stratified personalized cancer screening.

Our goal is to tackle difficult problems in human health and cancer biology. We work on the diseases of triple-negative breast cancer and other difficult-to-treat cancers.

Proper control of metabolism is required for essentially every basic biological process. Altered metabolism at the cellular level contributes to several serious diseases including inborn errors of metabolism (the result of inherited genetic defects in metabolic enzymes that lead to chemical imbalances in children) and cancer. Our laboratory seeks to characterize these metabolic disorders, understand how they compromise tissue function, develop methods to monitor metabolism in vivo and design therapies to restore normal metabolism and improve health.

Our lab is creating better experimental models that reveal how cancer cells metastasize and evade our immune system. We use these models to develop new drugs that engage our immune system to kill cancer cells.

• To understand how kidney cancer develops at the molecular level.
• To translate our findings into new treatments for kidney cancer patients.
• To train the next generation of physicians and scientists.

We are interested in the relationship between metabolism and cell type. We focus on the metabolism of hematopoietic stem cells (HSCs) and their progeny including cells of the myeloid and T cell lineages.